Perspectives of using influenza viruses expressing the protective mycobacterial antigene ESAT-6 for tuberculosis prophylaxis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Tuberculosis remains a major cause of morbidity and mortality all over the world. The only used Bacillus Calmette-Guerin (BCG) vaccine has failed to control the global tuberculosis epidemic, and there are no effective mucosal vaccines capable for potent protection against pulmonary ТВ.

In this study, we evaluated the immunogenicity and protective efficacy of a reverse genetic recombinant influenza vectors expressing the early secretory antigenic target protein (ESAT-6) of Mycobacterium tuberculosis in the experimental models of tuberculosis. Double immunization with recombinant influenza vectors of different subtypes induced a strong Th1 immune response mediated by IFN-gamma-secreting CD4 cells, which led to protection against tuberculosis in mice and guinea pigs equivalent to and even more than that observed with BCG vaccine.

Application of recombinant influenza vectors expressing ESAT-6 antigen of Mycobacterium tuberculosis was concluded to be perspective vaccine candidate against tuberculosis.

About the authors

M. A. Stuckova

Influenza Research Insitute RAMS

Author for correspondence.
Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 197376

N. V. Zabolotnikh

St. Petersburg Physiopulmonology Research Insitute

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 191036

T. I. Vinogradova

St. Petersburg Physiopulmonology Research Insitute

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 191036

S. Sereinig

Insitute of Applied Microbiology

Email: medaj@eco-vector.com
Austria, Vienna, A-1190

H. Katinger

Insitute of Applied Microbiology

Email: medaj@eco-vector.com
Austria, Vienna, A-1190

J. R. Romanova

Influenza Research Insitute RAMS; Insitute of Applied Microbiology

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 197376; Austria, Vienna, A-1190

J. N. Levashov

St. Petersburg Physiopulmonology Research Insitute

Email: medaj@eco-vector.com

член-корреспондент РАМН

Russian Federation, St. Petersburg, 191036

O. I. Kiselev

Influenza Research Insitute RAMS

Email: medaj@eco-vector.com

академик РАМН

Russian Federation, St. Petersburg, 197376

A. J. Egorov

Influenza Research Insitute RAMS; Insitute of Applied Microbiology

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 197376; Austria, Vienna, A-1190

References

  1. Левашев Ю. Н., Шеремет А. В., Григико А. Н. Туберкулез в Северо-Западном федеральном округе (2000-2004 гг.) // Пробл. туберкулеза и болезни легких. 2005. № 11. С. 3-6.
  2. Фрейдлин И. С., Тотолян А. А. Клетки иммунной системы. СПб., 2001. Т. 3. 390 с.
  3. Alexandrova G. L., Budilovsky G. N., Koval T. A. et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial // Vaccine. 1986. Vol. 2. P. 114-118.
  4. Andersen P. ТВ vaccines: progress and problems // Trends Immunol. 2001. Vol. 22. P. 160-168.
  5. Brandt L., Elhay M., Rosenkrands I. et al. ESAT-6 subunit vaccination against Mycobacterium tuberculosis // Infect. Immunol. 2000. Vol. 68. № 2. P. 791-795.
  6. Brodin P., Rosenkrands L., Andersen P. et al. ESAT-6 proteins: protective antigens and virulence factors? // Trends Microbiol. 2004. Vol. 12. № 11. P 500-508.
  7. Chackerian A. A., Perera T. V., Behar S. M. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis // Infect. Immunol. 2001. Vol. 69. № 4. P. 2666-2674.
  8. Demissie A., Abebe M., Aseffa A. et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Thl cytokines and the IL-4 antagonist IL-4delta2 // J. Immunol. 2004. Vol. 172. № 11. P 6938-6943.
  9. Ferko B., Stasakova J., Sereinig S. et al. Hyperattenuated recombinant influenza A virus non- structural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice // J. Virol. 2001. Vol. 19. P. 8899-8908.
  10. Fodor E., Devenish L., Engelhardt O. G. et al. Rescue of influenza A virus from recombinant DNA // J. Virol. 1999. Vol. 73. P. 9679-9682.
  11. Fulton S. A., Cross J. V., Toossi Z. T. et al. Regulation of interleukin-12 by interleukin-10, transforming growth factor-beta, tumor necrosis factor-alpha, and interferon-gamma in human monocytes infected with Mycobacterium tuberculosis H37Ra // J. Infect. Dis. 1998. Vol. 178. № 4. P 1105-1114.
  12. Hernandez-Pando R., Orozco H., Arriaga A. K. et al. Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice // Int. J. Exp. Pathol. 2000. Vol. 81. № 3. P 199-209.
  13. Hesse M., Modolell M., La Flamme A. C. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism // J. Immunol. 2001. Vol. 167. № 11. P 6533-6544.
  14. Kittel C., Sereinig S., Ferko B. et al. Rescue of influenza virus expressing GFP from the NS1 reading frame // Virology. 2004. Vol. 324. № 1. P. 67-73.
  15. Li Z., Howard A., Kelley C. et al. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences // Infect. Immunol. 1999. Vol. 67. № 9. P. 4780-4786.
  16. Mohammed К. A., Nasreen N., Ward M. J. et al. Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells // Am. J. Respir. Crit. Care Med. 1999. Vol. 159. № 5. Pt. 1. P. 1653-1659.
  17. Mollenkopf H. J., Groine-Triebkorn D., Andersen P. et al. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA // Vaccine. 2001. Vol. 19. № 28-29. P 4028-4035.
  18. Ordway D. J., Martins M. S., Costa L. M. et al. Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease // Acta Med. Port. 2005. Vol. 18. № 1. P.27-36.
  19. Oukka M., Manuguerra J. C., Livaditis N. et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides // J. Immunol. 1996. Vol. 157. P. 3039-3045.
  20. Phair J. P., Kauffman C. A., Jennings R. et al. Influenza virus infection of the guinea pig: immune response and resistance // Med. Microbiol. Immunol. (Berl). 1979. Vol. 165. № 4. P. 241-254.
  21. Rook G. A., Hernandez-Pando R., Dheda K. et al. IL-4 in tuberculosis: implications for vaccine design // Trends Immunol. 2004. Vol. 25. № 9. P. 483-488.
  22. Sauty A., Dziejman M., Taha R. et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells // J. Immunol. 1999. Vol. 162. № 4. P. 3549-3558.
  23. Stasakova J., Ferko B., Kittel C. et al. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins lbeta and 18 // J. Gen. Virol. 2005. Vol. 86. № 1. P. 85-95.
  24. Talbot E. A., Perkins M. D., Silva S. M. N. et al. Disseminated bacilli Calmette-Guerin disease after vaccination: case report and review // Clin. Infect. Dis. 1997. Vol. 24. P. 1139-1146.
  25. Talon J., Salvatore M., O’Neill R. E. et al. Influenza A and В viruses expressing altered NS1 proteins: A vaccine approach // Proc. Natl. Acad. Sci. 2000. Vol. 97. № 8. P. 4309-4314.
  26. Wang J., Thorson L., Stokes R. W. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis // J. Immunol. 2004. Vol. 173. № 10. P. 6357-6365.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.